GUIDING CLINICAL STUDIES IN PHASE 2&3
Drug development in oncology is a wide and challenging field. Screening of thousands and thousands of substances on a high throughput scale to generate a few possible drug candidate demands massive investments and is very time consuming.
Therefore it is highly desirable that drugs which are in the pipeline in clinical trial Phase II or Phase III will generate the expected success rate. To improve the hit rate, both time and financial resources can be saved if the testing system is more focused onto the clinical application at a very early phase. Loosing drug candidates simply because of the lack of expected efficiency must be avoided. Therefore with the right clinical trial design, only patients with positive in vitro diagnostic drug sensitivity profile should be discriminated and participate in the trial.
QantaScope HexascopeHAEMA™ automated scanner and image analyzer system as part of the CE IVD certified iVV assay™ diagnostic platform can be a perfect solution in patient preselection during the clinical study and later during market introduction.
The test is similar to iVV assay™ but the 384-well plates are developed according to the specific study requirements. Please contact our clinical trial team for further information.